1.
R&D in UK's
Pharmaceutical
Companies
Group #3:
Ahmed Abuiliazeed Diaa el Bagoury
Osama Hagag Mohamed Tarek

2.
Presentation Structure:
1. Overview.
2. UK Pharma Now and Then.
3. Problem Definition.
4. Research Methodology.
5. Challenges and Solutions

3.
Overview
● Competition with global market fueled the
need for more R&D activities and innovation.
● R&D staff size, and R&D expenditures lead
to more innovation in the company?
● Level of innovation compared to the relative
size of the corporation.
● Data sources:
○ Loss of easy access to data due to large company
mergers.
○ Power of public data records

4.
UK Pharma Industry Now:
● Economic value of the industry

5.
UK Pharma Industry Now:
● R&D expenditures by sector

6.
History
● Number of new chemical entities per year

7.
History
● Local vs Global Market

8.
Problem Definition
● UK falling behind competitors in the
pharmaceutical industry
○ Emerging economies
○ Developed economies
○ Lack of government investment
● Solutions:
○ Change business model
○ Actions against counterfeit medicine
○ Understanding global competition
○ Preventive medicine through focus on R&D

9.
Problem Definition
● Companies with more focus on R&D more
successful?
● Relation between innovation - company size.
● How to quantify innovation?
○ Papers
○ Patents
○ New drugs.
● Company size measured through R&D
○ R&D expenditure
○ Number of researchers.

10.
Research Methodology
● The hypothesis of the research was based
on finding relationship between research and
innovation.
● Claire decided to consider R&D expenditure,
Number of scientists employed as research
indicators.
● She also considered number of patents,
research papers and new drugs produced as
indicators for new innovations.

11.
Data Resources & Classification
1. Number of patents taken out of the company.
2. Number of scientific papers published by its scientists.
3. Number of drugs they've launched on the market
between 1960 and 1969.
4. Companies R&D expenditure.
5. Number of scientists employed in R&D departments.

12.
Data Resources & Classification
The data was collected from:
● 6 pharmaceutical companies
● Publications by the Department of trade, Department of
Health.
● Patent office
● National Economic Development Office.
● Reports from stockbrokers
● Association of British Pharmaceutical Industry (ABPI).
● Publications and good quality journalist Reports on the
Industry.

13.
Additional Resources
● Interviews with the R&D departments heads
of the top 10 Pharmaceutical companies in
UK.
● survey with 1000 participants from the
pharmaceutical industry.

14.
Research Challenges
& Solutions
● Company merges moved archives around.
● Difficult to get data from companies.
● Some of the public data available was under
a 30-year closure rule.
● Public data sometimes not comprehensive
enough.
Solution:
● Extract information from ministry of health
committees.
● Wait until data becomes available eventually

15.
Lessons Learned
● Keep an eye on the availability of data on
the subject, to not waste time or draw false
conclusions.
● Raw data from the primary sources would be
most accurate.

16.
References :
1. Research and development in the UK pharmaceutical industry in the
1960s.
2. The UK Pharmaceutical Industry: Current Challenges and Future
Solutions
3. Employment in the pharmaceutical industry in the UK
4. Pharmaceutical innovation by the seven UK-owned pharmaceutical
companies (1964-1985)

17.
Thanks